Unither Pharmaceuticals, Inc., (Sil...
Unither Pharmaceuticals, Inc., (Silver Spring, MD) reported deductions of a Phase 2 trial of OvaRex (oregovamab). The placebo-controlled trial in stage III/IV ovarian cancer enslaves identified a population that exhibited a vehemently favorable outcome. Median time to disease relapse for the close attention drug-treated subjects was 24 month versus 108 month for placebo-treated
|